Pharmacogenomics in gastrointestinal disorders

Michael Camilleri; Yuri A. Saito

doi:10.1007/978-1-59745-205-2_13

Pharmacogenomics in gastrointestinal disorders

Michael Camilleri, Yuri A. Saito

Research output: Chapter in Book/Report/Conference proceeding › Chapter

9 Scopus citations

Abstract

It is anticipated that unraveling the human genome will have a direct impact on the management of specific diseases. Variations or mutations in genes involved in drug metabolism or disease pathophysiology in gastroenterology and hepatology are expected to have effect on response to therapy. The spectrum of diseases is vast. Thus, we focus this review on clinical pharmacogenetics of inflammatory bowel disease, Helicobacter pylori infections, gastroesophageal reflux disease, irritable bowel syndrome, liver transplantation, and colon cancer. Although only a few genotyping tests are used regularly in clinical practice, we anticipate that in the future there will be more routine use of many of the tests described in this review.

Original language	English (US)
Title of host publication	Pharmacogenomics in Drug Discovery and Development
Subtitle of host publication	From Bench to Bedside
Publisher	Humana Press
Pages	395-412
Number of pages	18
ISBN (Print)	9781588298874
DOIs	https://doi.org/10.1007/978-1-59745-205-2_13
State	Published - 2008

Publication series

Name	Methods in Molecular Biology
Volume	448
ISSN (Print)	1064-3745

Keywords

Colon cancer
Functional dyspepsia
Functional gastrointestinal disorders
Gastroesophageal reflux disease
Helicobacter pylori infection
Inflammatory bowel disease
Irritable bowel syndrome
Liver transplantation
Pharmacogenetics

ASJC Scopus subject areas

Molecular Biology
Genetics

Access to Document

10.1007/978-1-59745-205-2_13

Cite this

@inbook{fb74aa0672aa4e9d9f5ac35909282ecf,

title = "Pharmacogenomics in gastrointestinal disorders",

abstract = "It is anticipated that unraveling the human genome will have a direct impact on the management of specific diseases. Variations or mutations in genes involved in drug metabolism or disease pathophysiology in gastroenterology and hepatology are expected to have effect on response to therapy. The spectrum of diseases is vast. Thus, we focus this review on clinical pharmacogenetics of inflammatory bowel disease, Helicobacter pylori infections, gastroesophageal reflux disease, irritable bowel syndrome, liver transplantation, and colon cancer. Although only a few genotyping tests are used regularly in clinical practice, we anticipate that in the future there will be more routine use of many of the tests described in this review.",

keywords = "Colon cancer, Functional dyspepsia, Functional gastrointestinal disorders, Gastroesophageal reflux disease, Helicobacter pylori infection, Inflammatory bowel disease, Irritable bowel syndrome, Liver transplantation, Pharmacogenetics",

author = "Michael Camilleri and Saito, {Yuri A.}",

year = "2008",

doi = "10.1007/978-1-59745-205-2_13",

language = "English (US)",

isbn = "9781588298874",

series = "Methods in Molecular Biology",

publisher = "Humana Press",

pages = "395--412",

booktitle = "Pharmacogenomics in Drug Discovery and Development",

}

TY - CHAP

T1 - Pharmacogenomics in gastrointestinal disorders

AU - Camilleri, Michael

AU - Saito, Yuri A.

PY - 2008

Y1 - 2008

N2 - It is anticipated that unraveling the human genome will have a direct impact on the management of specific diseases. Variations or mutations in genes involved in drug metabolism or disease pathophysiology in gastroenterology and hepatology are expected to have effect on response to therapy. The spectrum of diseases is vast. Thus, we focus this review on clinical pharmacogenetics of inflammatory bowel disease, Helicobacter pylori infections, gastroesophageal reflux disease, irritable bowel syndrome, liver transplantation, and colon cancer. Although only a few genotyping tests are used regularly in clinical practice, we anticipate that in the future there will be more routine use of many of the tests described in this review.

AB - It is anticipated that unraveling the human genome will have a direct impact on the management of specific diseases. Variations or mutations in genes involved in drug metabolism or disease pathophysiology in gastroenterology and hepatology are expected to have effect on response to therapy. The spectrum of diseases is vast. Thus, we focus this review on clinical pharmacogenetics of inflammatory bowel disease, Helicobacter pylori infections, gastroesophageal reflux disease, irritable bowel syndrome, liver transplantation, and colon cancer. Although only a few genotyping tests are used regularly in clinical practice, we anticipate that in the future there will be more routine use of many of the tests described in this review.

KW - Colon cancer

KW - Functional dyspepsia

KW - Functional gastrointestinal disorders

KW - Gastroesophageal reflux disease

KW - Helicobacter pylori infection

KW - Inflammatory bowel disease

KW - Irritable bowel syndrome

KW - Liver transplantation

KW - Pharmacogenetics

UR - http://www.scopus.com/inward/record.url?scp=84934436321&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84934436321&partnerID=8YFLogxK

U2 - 10.1007/978-1-59745-205-2_13

DO - 10.1007/978-1-59745-205-2_13

M3 - Chapter

C2 - 18370239

AN - SCOPUS:84934436321

SN - 9781588298874

T3 - Methods in Molecular Biology

SP - 395

EP - 412

BT - Pharmacogenomics in Drug Discovery and Development

PB - Humana Press

ER -

Pharmacogenomics in gastrointestinal disorders

Abstract

Publication series

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this